Update your tester profile Login
  • Studies for Particpants Diagnosed with Type 2 Diabetes

    Throughout 2015, Prism will be conducting several studies for participants diagnosed with type 2 diabetes.  These studies will be posted on our website once recuritment is officially underway.  

    Don't see a study listed?  Maybe a study is posted but it's not a match for you?  That's ok, we still want to hear from you!  Each study will have an unique set of qualifications.  Register with our database now so we can identify the right study for you as soon as it becomes availble.

    The information you provide is only used to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1514
    INTRODUCING A CLINICAL RESEARCH STUDY OF AN INVESTIGATIONAL VACCINE FOR EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI (E. COLI) OR ExPEC DISEASE
    A clinical research study assessing the safety and efficacy of an investigational vaccine in preventing ExPEC disease is now enrolling.  If you are interested in taking part in the ESTELLA Study, we are looking for men and women who: 
    • Are aged 18 years or over.
    • Are in stable health -- any symptoms of an illness must be medically controlled for at least 12 weeks prior to study treatment.
    • Have not received a vaccination 30 days prior to study treatment.

    There are other criteria that you will need to meet to join the study, which the study team will assess and discuss with you.  There will be no charge for treatment or any study-related care provided during the study.   

     

    If you'd like to learn more about enrolling in this clinical research study, visit www.estellastudy.com or contact:  

     

    Study Center: Prism Clinical Research

    Contact Person: Molly

    Address: 1000 Westgate Drive, St. Paul, MN 55114

    Telephone: 651-289-2096

    Email: mhair@prismresearchinc.com

     

    Participation is entirely voluntary and contacting us does not mean that you have to take part in this study.  

     

  • Study 1518 Cohort 2: Healthy Male and Female Participants

    Research Purpose: Study 1518 Cohort 2 is designed to evaluate an investigational drug being developed for the treatment of cancer. Participants will receive up to 3 intravenous (IV) doses of the investigational drug alone or along with companion medications.  Participants will also receive a single IV dose of a saline.  The following will be evaluated:

    • How the body’s immune system responds to the investigational drug
    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 18-25 kg/m²

    Weight

    Between 121-187 pounds

    Tobacco/Nicotine Use

    No more than the equivalent of 10 cigarettes/week in the 3 months prior to screen.  Able and willing to abstain from all tobacco use  for 14 days prior to screen until  the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Prescribed/stable hormonal birth control is allowed

    Allergy History

    No past or current allergy to baker’s yeast

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 4 weeks.

    Inpatient Stays

    • Participants will admit for inpatient stays at Prism Clinical Research 4 times
    • Each impatient stay will last approximately 24 hours (1 overnight)

    Outpatient Visits

    • There are a total of 8 outpatient visits throughout the study.
    • Each outpatient visit will last approximately 1 hour.

     

    Compensation for participation time:   Up to $1, 980.00

  • Study 1519 Cohort 3: Healthy Male and Female Participants

     

    Research Purpose: Study 1519 Cohort 3 is designed to evaluate an investigational drug being developed for the treatment of chronic inflammatory diseases. Participants will receive two separate oral doses of the investigational drug, once after a fast and once after a high fat meal.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    Between 18-32 kg/m²

    Tobacco/Nicotine Use

    No more than the equivalent of 5 cigarettes/week in the 2 months prior to screen.  Able and willing to abstain from all tobacco use  for 7 days prior to screen until  the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 years before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Some types of prescribed/stable hormonal birth control is allowed.

    Dietary Requirements

    Participants must be able and willing to eat/drink the following: eggs, dairy, pork, gluten

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 2 times
    • Each inpatient stay will last approximately 72 hours  (3 overnights)

    Outpatient Visits

    • There are a total of 11 outpatient visits 

     

    Compensation for participation time:   Up to $2,375

  • Study 1603: Healthy Male and Female Participants

    Research Purpose: Study 1603 is designed to evaluate an investigational drug being developed for the treatment of migraine.  Participants will receive the investiational drug in the form of a single dose given in the one of three different sub-cutaneous injection devices.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Use of non-hormonal birth control is required; hormonal birth control is not allowed.

    Age

    18-55years

    Body Mass Index (BMI)

    Between 18-30 kg/m²

    Tobacco/Nicotine Use

    No more than the equivalent of 10 cigarettes/day in the 30 days prior to the start of the study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 years before the start of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.  Any history of psychiatric illness such as anxiety, depression, or schizophrenia is not allowed.

    Restricted Medications

    Hormonal birth control is not allowed.  No required, regular use of any other prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 14 weeks.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time
    • The clinic stay will last approximately 36 hours  (1 overnight)

    Clinic Visits

    • There are 20 brief clinic visits following the inpatient stay (approximately 1 hour)

     

    Compensation for participation time:   Up to $2200.00

  • Study 1600: Healthy Male and Female Participants

    Research Purpose: Study 1600 is an investigational study of a medication called Armour® Thyroid which has been developed for the treatment of hypothyroidism (underactive thyroid).  Participants will receive a single oral dose of Armour® Thyroid on three separate occasions.  The following will be evaluated:

    •  How consistently the body processes and eliminates the investigational drug.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using hormonal birth control cannot participate.

    Age

    18-50 years

    Body Mass Index (BMI)

    Between 18-30 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco products 2 years prior to the start of the study.  Able and willing to abstain from tobacco use throughout the entire study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 5 years before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements.  Use of hormonal birth control is not allowed.

    Other Requirements

    Must have a working and reliable home or cell phone throughout the study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 3 times
    • Each inpatient stay will last approximately 72 hours  (3 overnights)

    Clinic Visits

    • There is 1 outpatient visit following the final inpatient stay (approximately 90 minutes)

    Phone Calls

    • Prism staff will call participants a minimum of 5 times throughout the study.

     

    Compensation for participation time:   Up to $2,500

Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel